Stock Analysis on Net
Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

$24.99

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Paying user area

Try for free

Eli Lilly & Co. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Eli Lilly & Co., consolidated cash flow statement

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income
Depreciation and amortization
Debt extinguishment loss
Change in deferred income taxes
Stock-based compensation expense
Net investment (gains) losses, net
Gains on sale of product rights
Acquired in-process research and development
Other operating activities, net
Receivables, (increase) decrease
Inventories, (increase) decrease
Prepaid expenses and other assets, (increase) decrease
Accounts payable and other liabilities, increase (decrease)
Other changes in operating assets and liabilities, net of acquisitions and divestitures
Adjustments to reconcile net income to cash flows from operating activities
Net cash provided by operating activities
Purchases of property and equipment
Proceeds from sales and maturities of short-term investments
Purchases of short-term investments
Proceeds from sales of and distributions from noncurrent investments
Purchases of noncurrent investments
Proceeds from sale of product rights
Purchases of in-process research and development
Cash paid for acquisitions, net of cash acquired
Other investing activities, net
Net cash used for investing activities
Dividends paid
Net change in short-term borrowings
Proceeds from issuance of long-term debt
Repayments of long-term debt
Purchases of common stock
Other financing activities, net
Net cash provided by (used for) financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Eli Lilly & Co. net cash provided by operating activities decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Net cash used for investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Eli Lilly & Co. net cash used for investing activities decreased from 2022 to 2023 and from 2023 to 2024.
Net cash provided by (used for) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Eli Lilly & Co. net cash provided by (used for) financing activities increased from 2022 to 2023 but then slightly decreased from 2023 to 2024.